GordonMD Global Investments
GordonMD Global Investments reported 14 stocks worth $166M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PYXS (21.8%), KYTX (18.5%) and TEVA (9.0%). Compared with Q2 2026, the fund opened new positions in TEVA, TNGX and ADRX, added to PYXS, KYTX and INCY, trimmed VIR, BLCO and TSHA and sold out of RARE, SION and INSM.
Latest filing: what GordonMD Global Investments did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PYXS Pyxis Oncology Inc | $36.2M | 21.8% | 15.5M | +5.5M (+55%) | 4 of 4 | |
| 2 | ![]() KYTX Kyverna Therapeutics Inc | $30.7M | 18.5% | 4.5M | +277K (+7%) | 4 of 4 | |
| 3 | ![]() TEVA Teva Pharmaceutical Industries Ltd | $15M | 9.0% | 380K | New position | 1 of 4 | |
| 4 | ![]() CLDX Celldex Therapeutics Inc | $9.1M | 5.5% | 280K | No change | 4 of 4 | |
| 5 | ![]() TNGX Tango Therapeutics Inc | $9M | 5.4% | 1.9M | New position | 1 of 4 | |
| 6 | ![]() VIR Vir Biotechnology Inc | $9M | 5.4% | 804K | −550K (−41%) | 4 of 4 | |
| 7 | ![]() ADRX Adarx Pharmaceuticals Inc | $9M | 5.4% | 450K | New position | 1 of 4 | |
| 8 | ![]() ALLO Allogene Therapeutics Inc | $8.5M | 5.1% | 5.3M | No change | 3 of 4 | |
| 9 | ![]() BLCO Bausch Plus Lomb Corp | $8.1M | 4.9% | 475K | −98K (−17%) | 4 of 4 | |
| 10 | ![]() EDIT Editas Medicine Inc | $8M | 4.8% | 3.1M | No change | 2 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →GordonMD Global Investments 13F FAQ
What does GordonMD Global Investments own?
GordonMD Global Investments reported 14 stocks worth $166M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PYXS (21.8%), KYTX (18.5%) and TEVA (9.0%). The table above lists every position in the filing (the top 10 without an account).
What did GordonMD Global Investments buy and sell in Q3 2026?
Compared with Q2 2026: 3 new positions, 3 added to, 5 trimmed and 5 sold out. New positions include TEVA, TNGX and ADRX. It sold all of RARE, SION and INSM.
When will GordonMD Global Investments file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is GordonMD Global Investments's portfolio worth?
The Q3 2026 filing reports $166M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
















